文献速递治疗药物监测与药物基因组学药物不良反应与药物警戒

从万古霉素谷浓度导向给药转换为两点采样AUC导向给药:某学术医疗中心的实施研究

Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center.
PubMed 文献 · Pharmacotherapy · 2019-03-18

该前瞻性观察性质量保证研究在学术医疗中心比较了万古霉素谷浓度导向给药与两点采样AUC导向给药的治疗目标达成情况。AUC导向组治疗AUC(400-800 mg·hr/L)达标率73.5%,显著高于谷浓度导向组的55%(p=0.0014),且超治疗AUC比例更低(1.7% vs 18%,p<0.0001),肾毒性无显著差异。

要点

  • AUC导向给药(两点采样)较谷浓度导向显著提高治疗达标率(73.5% vs 55%)。
  • AUC导向组超治疗暴露比例显著低于谷浓度组(1.7% vs 18%)。
  • 两组肾毒性发生率无显著差异(11% vs 9.4%,p=0.70)。

核心结论

  • 与谷浓度导向给药策略相比,基于两点采样的AUC导向给药改善了万古霉素治疗目标的达成。

研究设计与样本

  • 前瞻性观察性质量保证研究,纳入296例接受万古霉素治疗的住院成人患者。
  • 实施前回顾性对照组179例(2017年11月22日至2018年1月22日,谷浓度导向给药)。
  • 实施后组117例(2018年6月19日至7月19日,两点采样AUC导向给药)。

主要发现

  • 实施前组179例中仅98例(55%)初始谷浓度达标(10-20 mg/L)。
  • 实施后组117例中86例(73.5%)初始AUC达标(400-800 mg·hr/L),组间比较p=0.0014。
  • 实施后组超治疗AUC比例为1.7%,显著低于实施前组超治疗谷浓度比例18%(p<0.0001)。
  • 初始AUC达标患者中62%后续谷浓度升高≥25%,中位发生时间为万古霉素治疗第6天。
  • 肾毒性发生率实施前组11%,实施后组9.4%(p=0.70)。

关键数值与推荐

  • 治疗目标:AUC 400-800 mg·hr/L(AUC导向组)或谷浓度10-20 mg/L(谷浓度导向组)。
  • AUC值由峰浓度和谷浓度两点计算。

临床怎么用

  • 在开展万古霉素峰浓度检测的医院,可采用两点采样AUC导向给药作为贝叶斯软件估算AUC的可行替代方案。

局限性

  • 本研究为观察性质量保证研究,非随机对照设计,可能存在混杂因素。
  • 作者建议该两点采样AUC方法与贝叶斯软件估算AUC的方法进行直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: The optimal pharmacodynamic parameter for the prediction of efficacy of vancomycin is the area under the concentration-time curve (AUC), and current published data indicate that dosing based on vancomycin trough concentrations is an inaccurate substitute. In this study, our objective was to compare the achievement of therapeutic target attainment after switching from a trough-based to an AUC-based dosing strategy as a part of our institution's vancomycin-per-pharmacy protocol. DESIGN: Prospective observational quality assurance study. SETTING: Academic medical center. PATIENTS: A total of 296 hospitalized adults who received vancomycin and monitoring under our institution's vancomycin-per-pharmacy protocol were included in the analysis. The preimplementation retrospective comparison group consisted of 179 patients in whom vancomycin was initiated using a trough-based dosing strategy between November 22, 2017, and January 22, 2018. The postimplementation group included 117 patients in whom vancomycin was initiated using an AUC-based dosing strategy using two-point sampling between June 19, 2018, and July 19, 2018, after hospital-wide implementation of this protocol on June 19, 2018. MEASUREMENTS AND MAIN RESULTS: AUC values were calculated from two vancomycin concentrations (peak and trough). The primary outcome was achievement of therapeutic AUC values (400-800 mg·hr/L) in the postimplementation group or therapeutic trough level values (10-20 mg/L) in the preimplementation group. Only 98 (55%) of 179 initial trough values were therapeutic in the preimplementation group (trough-only dosing method) versus 86 (73.5%) of 117 initial AUC values in the postimplementation group (AUC-based dosing method) (p=0.0014). A lower proportion of supratherapeutic AUC values was observed in the postimplementation group compared with supratherapeutic trough concentrations in the preimplementation group (1.7% vs 18%, p<0.0001). Overall, 62% of patients with initially therapeutic AUC values had subsequent trough value increases of 25% or greater, occurring at a median of 6 days of vancomycin therapy. Nephrotoxicity occurred in 11% of patients in the preimplementation versus 9.4% in the postimplementation group (p=0.70). CONCLUSION: Compared with a trough concentration-based dosing strategy, AUC-based dosing using two-point sampling improved therapeutic target attainment. Implementation is feasible at any hospital that performs vancomycin peak concentration testing and is a workable alternative to using Bayesian software for estimating AUC. This approach should also be directly compared with AUC-based dosing using Bayesian software.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Meng L, Wong T, Huang S, et al. Conversion from Vancomycin Trough Concentration-Guided Dosing to Area Under the Curve-Guided Dosing Using Two Sample Measurements in Adults: Implementation at an Academic Medical Center. Pharmacotherapy. 2019. PMID: 30739349. doi:10.1002/phar.2234

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。